12-101757571-C-T
Position:
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_024312.5(GNPTAB):c.3335+1G>A variant causes a splice donor, intron change. The variant allele was found at a frequency of 0.0000129 in 1,390,032 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: 𝑓 0.000013 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000013 ( 0 hom. )
Consequence
GNPTAB
NM_024312.5 splice_donor, intron
NM_024312.5 splice_donor, intron
Scores
5
1
1
Splicing: ADA: 1.000
2
Clinical Significance
Conservation
PhyloP100: 7.04
Genes affected
GNPTAB (HGNC:29670): (N-acetylglucosamine-1-phosphate transferase subunits alpha and beta) This gene encodes two of three subunit types of the membrane-bound enzyme N-acetylglucosamine-1-phosphotransferase, a heterohexameric complex composed of two alpha, two beta, and two gamma subunits. The encoded protein is proteolytically cleaved at the Lys928-Asp929 bond to yield mature alpha and beta polypeptides while the gamma subunits are the product of a distinct gene (GeneID 84572). In the Golgi apparatus, the heterohexameric complex catalyzes the first step in the synthesis of mannose 6-phosphate recognition markers on certain oligosaccharides of newly synthesized lysosomal enzymes. These recognition markers are essential for appropriate trafficking of lysosomal enzymes. Mutations in this gene have been associated with both mucolipidosis II and mucolipidosis IIIA.[provided by RefSeq, May 2010]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
Splicing +-2 bp (donor or acceptor) variant, LoF is a know mechanism of disease, No cryptic splice site detected. Exon removal results in frameshift change.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 12-101757571-C-T is Pathogenic according to our data. Variant chr12-101757571-C-T is described in ClinVar as [Pathogenic]. Clinvar id is 2772.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr12-101757571-C-T is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GNPTAB | NM_024312.5 | c.3335+1G>A | splice_donor_variant, intron_variant | ENST00000299314.12 | NP_077288.2 | |||
GNPTAB | XM_011538731.3 | c.3254+1G>A | splice_donor_variant, intron_variant | XP_011537033.1 | ||||
GNPTAB | XM_006719593.4 | c.3335+1G>A | splice_donor_variant, intron_variant | XP_006719656.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GNPTAB | ENST00000299314.12 | c.3335+1G>A | splice_donor_variant, intron_variant | 1 | NM_024312.5 | ENSP00000299314.7 | ||||
GNPTAB | ENST00000550718.1 | c.146+1G>A | splice_donor_variant, intron_variant | 3 | ENSP00000449557.1 | |||||
GNPTAB | ENST00000549194.1 | n.201+1G>A | splice_donor_variant, intron_variant | 3 | ||||||
GNPTAB | ENST00000549738.5 | n.86+1G>A | splice_donor_variant, intron_variant | 4 | ENSP00000450161.1 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152146Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
2
AN:
152146
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000319 AC: 8AN: 251176Hom.: 0 AF XY: 0.0000442 AC XY: 6AN XY: 135800
GnomAD3 exomes
AF:
AC:
8
AN:
251176
Hom.:
AF XY:
AC XY:
6
AN XY:
135800
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000129 AC: 16AN: 1237768Hom.: 0 Cov.: 19 AF XY: 0.0000175 AC XY: 11AN XY: 627616
GnomAD4 exome
AF:
AC:
16
AN:
1237768
Hom.:
Cov.:
19
AF XY:
AC XY:
11
AN XY:
627616
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152264Hom.: 0 Cov.: 33 AF XY: 0.0000134 AC XY: 1AN XY: 74454
GnomAD4 genome
AF:
AC:
2
AN:
152264
Hom.:
Cov.:
33
AF XY:
AC XY:
1
AN XY:
74454
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
ExAC
AF:
AC:
6
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:9
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Mucolipidosis type II Pathogenic:5
Pathogenic, criteria provided, single submitter | clinical testing | Neuberg Centre For Genomic Medicine, NCGM | Jul 22, 2023 | The invariant splice donor site c.3335+1G>A variant in the GNPTAB gene has been observed in individuals in homozygous/ heterozygous state affected with Mucolipidosis Type II. Experimental studies have shown that this variant disrupts mRNA splicing Kudo et al., 2006; Costain et al., 2019. This variant is reported with an allele frequency 0.003% in the gnomAD. It has been submitted in the ClinVar database as Pathogenic multiple submissions. Loss of function variants have been previously reported to be disease-causing. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Foundation for Research in Genetics and Endocrinology, FRIGE's Institute of Human Genetics | Apr 13, 2023 | A Homozygous missense variation in intron 17 of the GNPTAB gene was detected. The observed variant c.3335+1G>A has not been reported in the 1000 genomes and has a MAF of 0.0032% in gnomAD databases. The in silico prediction of the variant are possibly damaging by MutationTaster2. The reference codon is conserved across species. In summary, the variant meets our criteria to be classified as pathogenic. - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 11, 2020 | - - |
Pathogenic, no assertion criteria provided | curation | GeneReviews | May 10, 2012 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Mar 01, 2006 | - - |
Pseudo-Hurler polydystrophy;C2673377:Mucolipidosis type II Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Sep 01, 2023 | This sequence change affects a donor splice site in intron 17 of the GNPTAB gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in GNPTAB are known to be pathogenic (PMID: 19617216, 25107912). This variant is present in population databases (rs34940801, gnomAD 0.03%). Disruption of this splice site has been observed in individuals with clinical features of GNPTAB-related conditions (PMID: 16465621, 32651481). This variant is also known as IVS17+1G>A. ClinVar contains an entry for this variant (Variation ID: 2772). Studies have shown that disruption of this splice site is associated with altered splicing resulting in skipping of exon 17 (PMID: 16200072, 16465621). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Apr 22, 2022 | - - |
Mucolipidosis Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Mar 05, 2021 | Variant summary: GNPTAB c.3335+1G>A is located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. Several computational tools predict a significant impact on normal splicing: Four predict the variant abolishes a 5' splicing donor site. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 3.2e-05 in 251176 control chromosomes. c.3335+1G>A has been reported in the literature in multiple individuals affected with Mucolipidosis supported by markedly elevated total serum hexosaminidase enzyme activity (example, Tiede_2005, Costain_2018, Pasumurthi_2020). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as pathogenic. - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Sep 20, 2023 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
GERP RS
Splicing
Name
Calibrated prediction
Score
Prediction
dbscSNV1_ADA
Pathogenic
dbscSNV1_RF
Pathogenic
SpliceAI score (max)
Details are displayed if max score is > 0.2
DS_DL_spliceai
Position offset: 1
Find out detailed SpliceAI scores and Pangolin per-transcript scores at